Investigating the domain specificity of phosphinic inhibitors RXPA380 and RXP407 in angiotensin-converting enzyme

Biochemistry

Volumn 48, Issue 35, 2009, Pages 8405-8412

  Kröger, Wendy L ^a   Douglas, Ross G ^a   O'Neill, Hester G ^b   Dive, Vincent ^c   Sturrock, Edward D ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b NORTH WEST UNIVERSITY   (South Africa)

^c SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN-CONVERTING ENZYME; BINDING AFFINITIES; C-DOMAIN; CARBOXYPEPTIDASE; DIFFERENT SUBSTRATES; DOMAIN SELECTIVITY; DOMAIN SPECIFICITY; DOUBLE MUTANTS; EXTRACELLULAR DOMAINS; HUMAN SOMATIC ANGIOTENSIN-CONVERTING ENZYMES; INHIBITION PROFILE; LARGE SHIFTS; MEMBRANE-BOUND; MOLECULAR BASIS; SELECTIVE INHIBITORS; SINGLE MUTATION; STRUCTURAL DATA;

BINDING ENERGY;

ENZYMES;

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROTEIN P2; RXP407; RXPA380; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; ENZYME KINETICS; HYDROLYSIS; PRIORITY JOURNAL;

BINDING SITES; HUMANS; MALE; MOLECULAR STRUCTURE; MUTATION; OLIGOPEPTIDES; PEPTIDYL-DIPEPTIDASE A; PHOSPHINIC ACIDS; SUBSTRATE SPECIFICITY;

EID: 69749126456     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi9011226     Document Type: Article

References (37)

1. Acharya, K. R., Sturrock, E. D., Riordan, J. F., and Ehlers, M. R. (2003) Ace revisited: a new target for structure-based drug design. Nat. Rev. Drug Discov. 2, 891-902.
2. Soubrier, F., Alhenc-Gelas, F., Hubert, C., Allegrini, J., John, M., Tregear, G., and Corvol, P. (1988) Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc. Natl. Acad. Sci. U.S.A. 85, 9386-9390.
3. Ehlers, M. R., Fox, E. A., Strydom, D. J., and Riordan, J. F. (1989) Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin- converting enzyme. Proc. Natl. Acad. Sci. U.S.A. 86, 7741-7745.
4. Langford, K. G., Zhou, Y., Russell, L. D., Wilcox, J. N., and Bernstein, K. E. (1993) Regulated expression of testis angiotensin-converting enzyme during spermatogenesis in mice. Biol. Reprod. 48, 1210-1218.
5. Wei, L., Alhenc-Gelas, F., Corvol, P., and Clauser, E. (1991) The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J. Biol. Chem. 266, 9002-9008.
6. Wei, L., Clauser, E., Alhenc-Gelas, F., and Corvol, P. (1992) The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J. Biol. Chem. 267, 13398-13405.
7. Voronov, S., Zueva, N., Orlov, V., Arutyunyan, A., and Kost, O. (2002) Temperature-induced selective death of the C-domain within angiotensin- converting enzyme molecule. FEBS Lett. 522, 77-82. (Pubitemid 34722501)
8. Jaspard, E., Wei, L., and Alhenc-Gelas, F. (1993) Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J. Biol. Chem. 268, 9496-9503.
9. Fuchs, S., Xiao, H. D., Hubert, C., Michaud, A., Campbell, D. J., Adams, J. W., Capecchi, M. R., Corvol, P., and Bernstein, K. E. (2008) Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension 51, 267-274. (Pubitemid 351159938)
10. Rousseau, A., Michaud, A., Chauvet, M. T., Lenfant, M., and Corvol, P. (1995) The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J. Biol. Chem. 270, 3656-3661.
11. Bicket, D. P. (2002) Using ACE inhibitors appropriately. Am. Fam. Physician 66, 461-468.
12. Morimoto, T., Gandhi, T. K., Fiskio, J. M., Seger, A. C., So, J. W., Cook, E. F., Fukui, T., and Bates, D. W. (2004) An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J. Eval. Clin. Pract. 10, 499-509.
13. Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A., and Agostoni, A. (1998) Plasma bradykinin in angio-oedema. Lancet 351, 1693-1697.
14. Beltrami, L., Zingale, L. C., Carugo, S., and Cicardi, M. (2006) Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it. Expert Opin. Drug Saf. 5, 643-649.
15. Ehlers, M. R. (2006) Safety issues associated with the use of angiotensin-converting enzyme inhibitors. Expert Opin. Drug Saf. 5, 739-740.
16. Georgiadis, D., Beau, F., Czarny, B., Cotton, J., Yiotakis, A., and Dive, V. (2003) Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. Circ. Res. 93, 148-154.
17. Peng, H., Carretero, O. A., Raij, L., Yang, F., Kapke, A., and Rhaleb, N. E. (2001) Antifibrotic effects of N-acetyl-seryl-aspartyl-lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats. Hypertension 37, 794-800. (Pubitemid 32199068)
18. Peng, H., Carretero, O. A., Liao, T. D., Peterson, E. L., and Rhaleb, N. E. (2007) Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension. Hypertension 49, 695-703. (Pubitemid 46263215)
19. Cavasin, M. A., Liao, T. D., Yang, X. P., Yang, J. J., and Carretero, O. A. (2007) Decreased endogenous levels of Ac-SDKP promote organ fibrosis. Hypertension 50, 130-136.
20. Dive, V., Cotton, J., Yiotakis, A., Michaud, A., Vassiliou, S., Jiracek, J., Vazeux, G., Chauvet, M. T., Cuniasse, P., and Corvol, P. (1999) RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc. Natl. Acad. Sci. U.S.A. 96, 4330-4335.
21. Georgiadis, D., Cuniasse, P., Cotton, J., Yiotakis, A., and Dive, V. (2004) Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain. Biochemistry 43, 8048-8054. (Pubitemid 38808259)
22. Corradi, H. R., Chitapi, I., Sewell, B. T., Georgiadis, D., Dive, V., Sturrock, E. D., and Acharya, K. R. (2007) The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380. Biochemistry 46, 5473-5478. (Pubitemid 46717270)
23. Watermeyer, J. M., Kröger, W. L., O'Neill, H. G., Sewell, B. T., and Sturrock, E. D. (2008) Probing the basis of domain-dependent inhibition using novel ketone inhibitors of angiotensin-converting enzyme. Biochemistry 47, 5942-5950.
24. Yu, X. C., Sturrock, E. D., Wu, Z., Biemann, K., Ehlers, M. R., and Riordan, J. F. (1997) Identification of N-linked glycosylation sites in human testis angiotensin-converting enzyme and expression of an active deglycosylated form. J. Biol. Chem. 272, 3511-3519.
25. Balyasnikova, I. V., Metzger, R., Franke, F. E., and Danilov, S. M. (2003) Monoclonal antibodies to denatured human ACE (CD 143), broad species specificity, reactivity on paraffin sections, and detection of subtle conformational changes in the C-terminal domain of ACE. Tissue Antigens 61, 49-62. (Pubitemid 36286749)
26. Corradi, H. R., Schwager, S. L., Nchinda, A. T., Sturrock, E. D., and Acharya, K. R. (2006) Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design. J. Mol. Biol. 357, 964-974.
27. Gordon, K., Redelinghuys, P., Schwager, S. L., Ehlers, M. R., Papageorgiou, A. C., Natesh, R., Acharya, K. R., and Sturrock, E. D. (2003) Deglycosylation, processing and crystallization of human testis angiotensin-converting enzyme. Biochem. J. 371, 437-442. (Pubitemid 36547627)
28. Ehlers, M. R., and Riordan, J. F. (1991) Angiotensin-converting enzyme: zinc- and inhibitor-binding stoichiometries of the somatic and testis isozymes. Biochemistry 30, 7118-7126.
29. Deddish, P. A., Wang, J., Michel, B., Morris, P. W., Davidson, N. O., Skidgel, R. A., and Erdös, E. G. (1994) Naturally occurring active N-domain of human angiotensin I-converting enzyme. Proc. Natl. Acad. Sci. U.S.A. 91, 7807-7811.
30. Friedland, J., and Silverstein, E. (1976) A sensitive fluorimetric assay for serumangiotensin-converting enzyme. Am. J. Clin. Pathol. 66, 416-424.
31. Schwager, S. L., Carmona, A. K., and Sturrock, E. D. (2006) A high-throughput fluorimetric assay for angiotensin I-converting enzyme. Nat. Protoc. 1, 1961-1964.
32. Araujo, M. C., Melo, R. L., Cesari, M. H., Juliano, M. A., Juliano, L., and Carmona, A. K. (2000) Peptidase specificity characterization of C- and N-terminal catalytic sites of angiotensin I-converting enzyme. Biochemistry 39, 8519-8525. (Pubitemid 30489949)
33. Eisenthal, R., and Cornish-Bowden, A. (1974) The direct linear plot. A new graphical procedure for estimating enzyme kinetic parameters. Biochem. J. 139, 715-720.
34. Dixon, M. (1953) The determination of enzyme inhibitor constants. Biochem. J. 55, 170-171.
35. Jullien, N. D., Cuniasse, P., Georgiadis, D., Yiotakis, A., and Dive, V. (2006) Combined use of selective inhibitors and fluorogenic substrates to study the specificity of somatic wild-type angiotensin-converting enzyme. FEBS J. 273, 1772-1781. (Pubitemid 43779829)
36. Tzakos, A. G., and Gerothanassis, I. P. (2005) Domain-selective ligand-binding m0odes and atomic level pharmacophore refinement in angiotensin I converting enzyme (ACE) inhibitors. ChemBioChem 6, 1089-1103.
37. Cohen, G. H. (1997) ALIGN: a program to superimpose protein coordinates, accounting for insertions and deletions. J. Appl. Crystallogr. 30, 1160-1161.